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The cardiorenal syndrome (CRS) is a complex clinical syndrome in which dysfunction of either the heart or the kidneys aﬀects
the functioning of the other organ system. Many therapies used in heart failure have further detrimental eﬀects on renal function.
Cardiac resynchronization therapy (CRT) is a relatively new form of device therapy that reduces morbidity and mortality in
patients with heart failure. This review will discuss the eﬀects of CRT on renal function in patients with CRS, the impact of
baseline renal function on response to CRT, and potential risks associated with CRT in this unique population.
1.Introduction
It has long been recognized that heart failure and renal
impairment frequently coexist and that functional decline in
one organ system is often associated with a parallel decline
in the other. In the past decade, the term “cardiorenal sy-
ndrome” (CRS) has been used to describe this complex
process. Although initially described as a state in which
“therapy to relieve congestive symptoms of heart failure
is limited by further decline in renal function,” [1] newer
deﬁnitions and classiﬁcation schemes have tried to capture
thebidirectionalfeedbackprocessesandcomplexpathophys-
iological interactions which exist between the heart and the
kidneys. The CRS is not simply renal dysfunction as a result
ofa low-ﬂow stateinducedbydepressed cardiac function but
rather a complex clinical syndrome in which hemodynamic
abnormalities,neurohormonal activation,inﬂammation and
oxidative stress cause dysfunction of both organ systems
through symbiotic pathways [2]. In recognition of these
complex interactions, Ronco and colleagues recently pre-
sented a classiﬁcation system for CRS (Table 1)[ 3]. It is well
recognized that an individual can simultaneously exhibit the
pathophysiological characteristics of multiple types of CRS
and that this classiﬁcation scheme is not meant to discretely
categorize patients into subgroups.
As our understanding of the underlying mechanisms of
CRS has progressed, so has our recognition of the mag-
nitude of the problem and of its prognostic signiﬁcance.
In ADHERE, a national registry of more than 100 000
nonselected patients admitted to hospital with acute decom-
pensated heart failure, 31% of patients had chronic renal
insuﬃciency, 20% had serum creatinine levels >2.0mg/dL,
and 5% were receiving dialysis [4]. Furthermore, even
moderate renal insuﬃciency is associated with increased
mortality in patients with symptomatic or asymptomatic
LV dysfunction [5] or heart failure with preserved systolic
function [6]; creatinine clearance predicts mortality inde-
pendent of ejection fraction or functional capacity [7]. In
the Studies of Left Ventricular Dysfunction (SOLVD) trials,
decline in GFR was independently associated with increased
risk of mortality in patients with heart failure, regardless
of baseline renal function [8]. In patients admitted to
hospital with heart failure, worsening renal function during
admission predicts in-hospital mortality, complications, and
longer duration of hospitalization [9]. On the other hand,
cardiovascular disease including heart failure is common in
patients with renal failure, and cardiovascular death is the
leadingcauseofmortalityamongrenal cohorts[10].Therisk
ofcardiovasculareventsincreasesrapidlywithdecliningGFR
[10].2 International Journal of Nephrology
Table 1: Classiﬁcationsystem of cardiorenal syndrome (CRS).
Description Examples of inciting events Examples of consequences
Type 1 CRS Acute HF leads to AKI
(i) ADHF (i) AKI
(ii) Cardiogenic shock (ii) Diuretic resistance
(iii) Hypertensive pulmonary edema
Type 2 CRS Chronic HF leads to
progressive CKD
(i) Chronic systolic HF (i) Progressive CKD
(ii) Chronic HF with preserved systolic
function
Type 3 CRS Acute renal dysfunction leads
to acute cardiac dysfunction
(i) AKI (i) ADHF
(ii) Glomerulonephritis (ii) Acute HF
(iii) Ischemia
(iv) Arrhythmia
(v) Decreased CO
Type 4 CRS
CKD leads to chronic cardiac
dysfunction and/or increased
risk of CV events
(i) CKD (i) Systolic dysfunction
(ii) LVH
(iii) Diastolic dysfunction
(iv) Coronary calciﬁcation
(v) Decreased coronary perfusion
Type 5 CRS Systemic disorder leads to
cardiac and renal dysfunction
(i) Sepsis (i) Acute HF
(ii) Vasculitis (ii) Chronic HF
(iii) Diabetes (iii) AKI
(iv) Amyloidosis (iv) CKD
Adapted from [3]. ADHF: acutely decompensated heart failure; AKI: acute kidney injury; CKD: chronic kidney disease; CO: cardiac output; CV:
cardiovascular; HF: heart failure; LVH: left ventricular hypertrophy.
Pharmacologic therapies for heart failure are often limit-
edbyadverseeﬀectsonrenal function.Althoughangiotensin
converting enzyme inhibitors (ACEIs), angiotensin II recep-
tor blockers (ARBs), and aldosterone antagonists all prolong
survival in heart failure patients [11–16], they are relatively
contraindicated in patients with unstable renal function and
may cause acute declines in glomerular ﬁltration rate (GFR).
Furthermore, most trials evaluating the eﬃcacy of these
therapies in heart failure excluded patients with evidence of
signiﬁcant renal dysfunction. Similarly, loop diuretics, which
have never been demonstrated to improve outcomes in
heart failure, are the mainstay of symptomatic treatment for
volume overload and are frequently associated with a decline
in renal function. Moreover, there is emerging data to suggest
an increase in mortality with the use of these agents [17].
Pharmacological therapy centered on neurohormonal
blockade remains ﬁrst-line therapy for the majority of
patients with systolic left ventricular dysfunction [18–20].
However, for those with advanced functional symptoms and
depressed LV function, despite optimization of evidence-
based HF therapies, cardiac resynchronization therapy may
provide additional morbidity and mortality beneﬁts.
In up to 30% of patients with heart failure, intra-
ventricular conduction delay produces mechanical dyssyn-
chrony, resulting in ineﬃcient ventricular contraction and
negative remodeling. Biventricular pacing may restore syn-
chronous contraction of the interventricular septum and
LV free wall with resultant improvement in LV geometry
and function. Cardiac resynchronization therapy (CRT)
improves symptoms, functional classiﬁcation, echo param-
eters (including left ventricular ejection fraction and end-
systolic volume, mitral regurgitation severity, and interven-
tricular mechanical delay) and prolongs survival in patients
with intraventricular conduction delay (QRS complex width
>120ms), LVEF ≤35%, and New York Heart Association
(NYHA) class III-IV symptoms [21–24]. As such, each of the
major societies’ guidelines recommends CRT in this patient
population [18–20].
2. Effect ofCardiacResynchronization Therapy
onRenalFunction
Our understanding of the impact of CRT on renal function
in patients with CRS has been limited by the exclusion of
patients with renal failure from many randomized, clinical
trials. TheMIRACLEtrialwasadouble-blinded,randomized
and placebo-controlled trial in which patients with NYHA
class III or IV symptoms, QRS duration ≥130ms, LVEF
≤35%, and LV end-diastolic diameter ≥55mm underwent
implantation of a CRT device and were randomized to
device on (treatment group) or device oﬀ (control group)
[23]. Patients were excluded from the trial if their serum
creatinine was >3.0mg/dL. In a retrospective analysis of
the MIRACLE trial [25], Boerrigter and colleagues assessed
the eﬀect of CRT on estimated GFR (eGFR) in patients
falling into three categories: normal or increased eGFR
(≥90mL/min/1.73m2), mildly reduced eGFR (60 ≤ eGFRInternational Journal of Nephrology 3
< 90mL/min/1.73m2), and moderately reduced eGFR (30
≤ eGFR ≤ 60mL/min/1.73m2). CRT signiﬁcantly improved
eGFR compared to control in patients with moderately re-
duced eGFR, but it had no eﬀect in patients with normal,
increased or mildly decreased eGFR. In patients with a base-
line eGFR ≤ 60mL/min/1.73m2, there were fewer patients
in the treatment group than in the control group who expe-
rienced worsening renal function.
Similar observations have been made in nonrandomized
studies. Adelstein and colleagues demonstrated that com-
pared to standard deﬁbrillator (SD) therapy, CRT-deﬁbril-
lator (CRT-D) implantation was associated with improved
renal function, as well as improved survival and improved
LV systolic function on echocardiogram, in patients with
baseline GFR 30–59mL/min/1.73m2 [26]. Patients with
GFR ≤30mL/min/1.73m2 showed improved renal func-
tion but not improved survival after CRT-D implantation,
while renal function deteriorated in those with GFR ≥
60mL/min/1.73m2. Although the authors did not speciﬁ-
cally address the reason for the decline in this latter group,
they did hypothesize that preserved renal function may be
a surrogate for relatively compensated heart failure. The
declinein GFR in this group couldreﬂect the risks associated
with device implantation (see below) or simply the natural
progression of the cardiorenal syndrome, superimposed on
minimal hemodynamic beneﬁt of CRT at the level of the
kidney. In another study, patients who were “responders” to
CRT (those who demonstrated any improvement in LVEF
after CRT implantation) showed mild improvement in GFR,
while those who were “nonresponders” showed a decline
in renal function [27]. As in other studies, this eﬀect was
even more pronounced in patients with baseline eGFR
< 60mL/min. Perhaps as a result of this, prescription of
ACEI and ARB therapy increased in “responders”, while it
decreased in “nonresponders”. ACEI and ARB therapies have
a well-established survival beneﬁt in HF patients, regardless
of GFR [28], and the ability to oﬀer them to patients may
contribute to the overall beneﬁt of CRT. In a similar study
by Fung and colleagues, patients with a 10% reduction in
LV end-systolic volume (LVESV) after CRT implantation
maintained stable renal function, while those who failed
to show improvement in LVESV had a signiﬁcant decline
in GFR [29]. From the limited data available, it appears
that CRT-implantation, particularly when associated with
improved LV function, is associated with improved renal
function in patients with baseline renal impairment.
The proposed mechanisms by which CRT may improve
renal function are based onourcurrent understanding of the
pathophysiologyof renal failure in the broader contextof the
cardiorenal syndrome. Historically, it was believed that renal
failure was a result of renal hypoperfusion, in turn, due to
reduced cardiac output and diuretic-induced intravascular
volume depletion [30]. More recently, it has been recognized
that elevated central venous pressure may play an equally or
even more important role in the progression of renal failure
among HF patients. Increased right-sided ﬁlling pressures
ultimately lead to renal congestion, reduced renal perfusion
pressure, and direct ischemic injury as a result of increased
interstitial pressure in the renal medulla [31, 32]. CRT may
mitigate these processes, in part due to improved cardiac
output[24,33]andincreasedmeanarterial pressure[22,34].
It also leads to reductions in central venous pressure [34],
and therefore, may improve renal perfusion by improving
both “forward” and “backward” cardiac failure.
Neurohormonal activation may also play a role in the
pathogenesis of the cardiorenal syndrome. Heart failure
is clearly associated with activation of the sympathetic
nervous system (SNS), the renin-angiotensin-aldosterone
system (RAAS) and cardiac natriuretic peptides. Although
the speciﬁc roles of these messenger pathways at the level
of the kidney are still being elucidated, there is indirect
evidence to suggest that interruption of both renal sym-
pathetic innervation and of RAAS activation may produce
beneﬁcial renal eﬀects[2].Althoughcatecholamine levelsare
not reduced with CRT [25], sympathetic nerve activity is
diminished [35, 36], suggesting decreased adrenergic tone
with CRT. In addition, long-term CRT is associated with
reducedRAASactivityandstabilizationofNT-proBNPlevels
in patients who demonstrate reverse LV remodeling but not
in those who do not reverse remodel [37]. Taken together,
these ﬁndings suggest that in addition to the beneﬁts
achieved through direct hemodynamic eﬀects, CRT may
positively impact renal function by interrupting deleterious
neurohormonal pathways that are hypothesized to be culprit
in the pathophysiology of heart failure.
3.EffectofRenalDysfunction onResponseto
CardiacResynchronization Therapy
Baseline renal function may predict response to CRT both in
terms of mortality and other clinically important endpoints.
Shalaby and colleagues retrospectively studied 330 patients
receiving CRT and found that those in the highest tertile of
serum creatinine (1.4–3.0mg/dL) had the highest mortality
rate (28.7% versus 14.0% in other tertiles, P = .008) as well
asthehighestrateofthecombinedendpointofmortalityand
heart failure hospitalization (41.6% versus 21.5%, P = .001)
[38]. When studied as a continuous variable, each 0.1mg/dL
increase in creatinine was associated with an 11% increase
in mortality and a 7% increase in the combined endpoint.
Several other studies have similarly demonstrated that renal
function is an independent predictor of survival [39, 40]a n d
survival-free from heart transplantation or ventricular assist
device (VAD) [41, 42] in patients receiving CRT and that
the mortality beneﬁt achieved with CRT-D over standard
deﬁbrillator therapy may be attenuated or lost at low eGFR
[26]. The change in GFR following CRT implantation may
also predict long-term outcomes. Fung and colleagues were
able to demonstrate that patients whose renal function
remained stable at 3 months after CRT implantation had
lower all-cause mortality and lower combined mortality and
HF hospitalization than those whose renal function declined
[29].
Interestingly, in the same study [29], the group of
patients who responded to CRT as characterized by LV
reverse remodeling had worse renal function at baseline than
the group who did not respond. Other investigators have4 International Journal of Nephrology
shown that LV mass may decrease and 6-minute walk dis-
tance may increase after CRT implantation in patients with
eGFR < 60mL/min/1.73m2 to a greater extent than in
patients with eGFR ≥ 60mL/min/1.73m2 [25]. These ﬁnd-
ings may reﬂect the fact that while renal insuﬃciency is
associated with a poor overall prognosis that cannot be
completely reversed with current therapies, patients with
reduced GFR have the most to gain from reversal of the neu-
rohormonal and hemodynamic disturbances associated with
heart failure.
4.AdverseRenalConsequencesof
CardiacResynchronization Therapy:
Contrast-InducedNephropathy
While there are many potential beneﬁts to CRT in patients
with theCRS,noprocedureisentirelywithoutrisks. Implan-
tation of the left ventricular lead typically requires contrast
administration in order to locate the ostium of the coronary
sinus and to deﬁne coronary venous anatomy. Contrast-
inducednephropathy(CIN),typicallydeﬁnedasanelevation
in serum creatinine of ≥25% following intravenous contrast
administration, is frequently reported after other procedures
such as coronary angiography and is associated with adverse
outcomes including mortality [43]. Major risk factors for
CIN include preexisting renal dysfunction, diabetes mellitus,
congestive heart failure, volume of contrast used, female
sex, and mean arterial pressure <100mmHg [43–45]. In one
study, CIN occurred in 10 of 68 patients (14%) undergoing
CRT implantation; three of these patients required hemoﬁl-
tration, and one died [46]. The incidence of CIN was higher
(63%) in patients with baseline creatinine ≥200umol/L, and
CIN was associated with longer duration of hospital stay (19
versus 4 days, P<. 0 1 ) .E p i c a r d i a lL Vl e a dp l a c e m e n t ,v i aa n
open surgical procedure, has been proposed as an alternative
in patients with renal insuﬃciency [47]. Although this
approach is more invasive than catheter-based transvenous
lead placement and is associated with longer ICU stay, it
avoidstheuseofintravenouscontrastdyeandmaybeequally
eﬀective [48].
5.Conclusions
CRS is an important clinical syndrome aﬀecting a large
proportion of patients with primary heart failure, primary
kidneydisease, orbothand is associated with a poorprogno-
sis. Many pharmacologic therapies used in the management
of heart failure have the potential to worsen renal function,
particularlyinpatientswhoalready havebaselinerenalinsuf-
ﬁciency. Cardiac resynchronization therapy is an additional
tool which can be used to manage this complex patient
population; CRT may have the added beneﬁt of speciﬁcally
targeting many of the underlying pathophysiological mech-
anisms which are felt to be central to the propagation of
CRS and data suggest that it may also be an eﬀective means
of treating heart failure while improving renal function in
this population. CRS patients are at particularly high risk
of mortality and other adverse events and they may remain
at higher risk than isolated HF patients when treated with
CRT, but the limited amount of available data suggests that
they are still able to obtain some beneﬁt from this therapy.
More studies of CRT in this speciﬁc population, and in the
individual subtypes of CRS, as well as the inclusion of CRS
patients in large clinical trials, will allow a greater under-
standing of its impact on this important disease.
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